HashiCorp shares jump on report that company is considering a sale
HashiCorp at the Nasdaq market site, December 9, 2021.
Source: Nasdaq
HashiCorp shares jumped 12% in extended trading on Friday after Bloomberg reported the software developer was considering a sale.
The company has engaged an outside firm to explore interest from potential buyers, Bloomberg said, citing unnamed sources. A company representative didn’t immediately respond to CNBC’s request for comment.
HashiCorp, whose software helps developers control resources in public clouds and data centers, debuted on the Nasdaq in late 2021, right at the peak of the tech market. The stock dropped 14% last year while the S&P 500 posted a 24% gain.
As of Friday’s close, HashiCorp was trading at $26.50, or 67% below its initial public offering price. Its market cap sits at around $5 billion. In the latest quarter, revenue growth slowed to 15% from 41% a year earlier.
“We are behind where we wanted the company to be at this point in our growth cycle, and we have work to do,” CEO David McJannet said on a conference call with analysts last week.
Mitchell Hashimoto, a co-founder and former technology chief of HashiCorp, said in December that he was leaving the company.
Read Bloomberg’s full report here.
Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025.
Gerry Miller | CNBC
Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.
Claude for Life Sciences is built around Anthropic’s existing AI models, but supports new connections with other scientific tools that are commonly used in labs during research and development.
It will be able to help researchers through all stages of the discovery process, from carrying out literature reviews to developing hypotheses, analyzing data, drafting regulatory submissions and more, Anthropic said.
The launch of Claude for Life Sciences marks Anthropic’s first formal entry into the sector, and comes just months after the company hired longtime industry executive Eric Kauderer-Abrams as its head of biology and life sciences.
“Now is the threshold moment for us where we’ve decided this is a big investment area,” Kauderer-Abrams told CNBC in an interview. “We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding.”
Anthropic, which is one of the companies at the center of the AI boom, develops a family of large language models called Claude. It was founded in 2021 by a group of former OpenAI executives and researchers, and its valuation has swelled to $183 billion in just four years.
The company launched a new model, Claude Sonnet 4.5, late last month and said it is “significantly better” at life sciences tasks like understanding laboratory protocols.
Kauderer-Abrams said researchers have already been engaging with Anthropic’s models to help with isolated parts of the scientific process, so the company decided to formally build out Claude for Life Sciences as a way to support them from start to finish.
That meant Anthropic had to establish integrations with key players in the life sciences ecosystem, including Benchling, PubMed, 10x Genomics and Synapse.org, among others. Anthropic has also partnered with companies that can help life sciences organizations adopt AI, like Caylent, KPMG, Deloitte, and cloud providers AWS and Google Cloud, the company said.
“We’re willing and enthusiastic about doing that grind to make sure that all the pieces come together,” Kauderer-Abrams said.
In a prerecorded demo, Anthropic showed how a scientist working on preclinical studies could use Claude for Life Sciences to compare two study designs that test different dosing strategies.
The scientist was able to query her lab’s data directly from Benchling, generate a summary and tables of key differences with links back to the original material. After reviewing the results, the scientist generated a study report that could be included in a regulatory submission.
Anthropic said an analysis like this used to require “days” of validating and compiling information, but now, it can be done in minutes.
Kauderer-Abrams said the company believes AI can bring about real efficiency gains for the life sciences sector, but it’s also under “no illusions” that it will magically overcome the physical limitations of conducting scientific research. Clinical trials that take three years are not suddenly going to take one month, he said.
Instead, Anthropic is focused on exploring the time-consuming, expensive parts of the discovery process “piece by piece” to determine where AI could be most useful.
“We’re here to make sure that this transformation happens and that it’s done responsibly,” Kauderer-Abrams said.
WATCH: Anthropic launches Claude Sonnet 4.5, its latest AI model
-
Sports3 years ago‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
-
Sports2 years agoStory injured on diving stop, exits Red Sox game
-
Sports2 years agoGame 1 of WS least-watched in recorded history
-
Sports3 years agoButton battles heat exhaustion in NASCAR debut
-
Sports3 years agoMLB Rank 2023: Ranking baseball’s top 100 players
-
Sports4 years ago
Team Europe easily wins 4th straight Laver Cup
-
Environment2 years agoJapan and South Korea have a lot at stake in a free and open South China Sea
-
Environment1 year agoHere are the best electric bikes you can buy at every price level in October 2024